<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200415047083N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-14</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of Garlic tablet as a treatment of macular edema of patients with  diabetic retinopathy</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of  the effect of Garlic tablet as a complementary treatment of macular edema of patients with  diabetic retinopathy in comparison with placebo, double blind randomized placebo controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-07-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>96</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/47451</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In each clinic a random number (for example between 0-1)  is produced by calculator or computer for each patient  and if this number is lower than  a limit number ( for example 0.5) that patient is selected as a case and if upper as a control or viceversa.
Or : A number is allocated to each patient .Random numbers( equal to number of case or control group) produced by using calculator or computer .Patients are divided into two groups by using  random numbers, Blinding description: In this study, patients were randomly assigned to two groups: case and control. All patients receive standard treatment for macular diabetic edema (intravenous injection of Bevacizumab or retinal laser) under the supervision of a physician. The therapist has no information about the case and control individuals.patients on the case group are given garlic tablets at a dose of 1000 mg daily for 4 weeks (if possible 2or 3 months for some patients). The other group is given a placebo in the form of a pill with the same packaging as the Garlic supplement.</study_design>
      <phase>3</phase>
      <hc_freetext>Macular edema in patients with diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A complete examination of the anterior and posterior segments is performed for patients in this group. and the best corrected visual acuity is measured based on the Snellen chart, and optical coherence tomography is done for all the patients. All patients receive standard treatment for macular diabetic edema (intravenous injection of Boasizumab or retinal laser). Patients in the intervention group receive Garlic tablet with a dose of 1000 mg daily with lunch  for 1 month (if possible for some patients 2 or 3 months).After 1 month, the best corrected visual acuity and optical coherence tomography is performed and macula thickness is measured. Intervention 2: Control group: A complete examination of the anterior and posterior segments is performed for patients in this group. and the best corrected visual acuity is measured based on the Snellen chart, and optical coherence tomography is done for all the patients. All patients receive standard treatment for macular diabetic edema (intravenous injection of Boasizumab or retinal laser). Patients in the control group receive placebo tablet daily with lunch for 1 month (if possible for some patients 2 or 3 months).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Dissatisfaction of some patients and colleagues.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Elham sadegi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Ophthalmology, Poostchi Ophthalmology Research Center, Asadabadi Ave., Zand Blvd., Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134997446</zip>
        <telephone>0987132330073</telephone>
        <email>elham.sadeghi@rocketmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehrdad Afarid</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Ophthalmology, Poostchi Ophthalmology Research Center, Asadabadi Ave., Zand Blvd., Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134997446</zip>
        <telephone>0987132330073</telephone>
        <email>afaridm@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diabetic patients with macular edema</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Oral or intravenous injection of corticosteroids and Immunomodulatory therapy
History of vitrectomy surgery
Warfarin and Plavix and Heparin
History of  chemotherapy and active gastrointestinal ulcers
History of cerebral hemorrhage</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11.311</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes mellitus with unspecified diabetic retinopathy with macular edema</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A complete examination of the anterior and posterior segments is performed for patients in this group. and the best corrected visual acuity is measured based on the Snellen chart, and optical coherence tomography is done for all the patients. All patients receive standard treatment for macular diabetic edema (intravenous injection of Boasizumab or retinal laser). Patients in the intervention group receive Garlic tablet with a dose of 1000 mg daily with lunch  for 1 month (if possible for some patients 2 or 3 months).After 1 month, the best corrected visual acuity and optical coherence tomography is performed and macula thickness is measured.</i_keyword>
      <i_keyword>Control group: A complete examination of the anterior and posterior segments is performed for patients in this group. and the best corrected visual acuity is measured based on the Snellen chart, and optical coherence tomography is done for all the patients. All patients receive standard treatment for macular diabetic edema (intravenous injection of Boasizumab or retinal laser). Patients in the control group receive placebo tablet daily with lunch for 1 month (if possible for some patients 2 or 3 months).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Macula thickness. Timepoint: Before starting the intervention and 1 month later after taking garlic tablets and placebo. Method of measurement: Optical coherence tomography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Best Corrected Visual Acuity. Timepoint: Before starting the intervention and 1 month later after taking garlic tablets and placebo. Method of measurement: Snellen chart.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-04-26</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Department of Ophthalmology, Poostchi Ophthalmology Research Center, Asadabadi Ave., Zand Blvd., Shiraz, Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
